What Dalfaz Treats: Main Uses and Benefits

Dalfaz (Alfuzosin) is used for the long-term symptomatic management of urinary difficulties in adult men with an enlarged prostate, a condition known as Benign Prostatic Hyperplasia (BPH). It is applied to address the spectrum of symptoms known as Lower Urinary Tract Symptoms (LUTS). The medication is used in conditions where symptoms are linked to organ-specific functional stress and where supportive symptom management is appropriate.

Therapeutic Focus

The therapeutic context involves helping manage symptom clusters related to flow and storage, such as restricted urine flow, hesitancy, a weak urinary stream, urinary frequency, and nocturia. This symptomatic relief helps ease the overall symptom burden caused by flow restriction and contributes to improved day-to-day comfort.

“The primary goal of this therapy is to help ease the overall symptom burden caused by flow restriction and contributes to improved day-to-day comfort.”

---

Quick Fact: Relief for BPH Symptoms

The medication supports patients during episodes of heightened discomfort by helping to ease disruptive nighttime manifestations and assisting with maintaining functional stability. It is applied in clinical settings that involve chronic, noticeable symptom patterns.

Regulatory References

1. NIH MedlinePlus overview of Alfuzosin

Dalfaz (Alfuzosin) eligibility is strictly defined by regulatory authorities and is limited to adult men for the treatment of Benign Prostatic Hyperplasia (BPH). The medication is not indicated for use in women, including those who are pregnant or breastfeeding, nor is it indicated for the pediatric population, as safety and efficacy have not been established. Use in older adults is generally permitted.

Use is absolutely contraindicated in several specific populations due to unacceptable risk:

Exclusionary Condition	Affected Population
Moderate to severe hepatic impairment	Liver function compromised
Concomitant use of potent CYP3A4 inhibitors	Taking medications like ketoconazole or ritonavir
Concomitant use of other alpha-1 blockers	Taking similar class medications
Previous history of orthostatic hypotension	History of low blood pressure when standing
Known hypersensitivity	Allergy to alfuzosin or other quinazolines

Additionally, Dalfaz is not recommended or requires caution in patients with severe renal impairment (creatinine clearance less than 30 mL/min) and those with certain pre-existing cardiac conditions, such as congenital QT prolongation or when symptoms of angina pectoris appear or worsen.

Dalfaz, which contains alfuzosin, has important interactions documented in regulatory information, primarily categorized by the risk of increased drug exposure or additive effects on blood pressure.

Contraindicated Combinations

Co-administration is strictly contraindicated with two major drug categories:

• Other Alpha-Adrenergic Receptor Blockers: The use of Dalfaz in combination with any other alpha-blocker is prohibited due to the potential for compounded effects, primarily leading to severe hypotension (low blood pressure).
• Potent CYP3A4 Inhibitors: Alfuzosin is metabolized by the enzyme CYP3A4. Strong inhibitors of this enzyme, such as ketoconazole, itraconazole, and ritonavir, significantly increase alfuzosin plasma levels, raising the risk of adverse reactions.

Use with Caution

Increased caution and clinical monitoring are required when Dalfaz is taken with the following agents due to the potential for excessive blood pressure lowering effects:

• Antihypertensive Medicines: Combining Dalfaz with medicines for high blood pressure (antihypertensives) can increase the risk of symptomatic hypotension, dizziness, and fainting.
• Nitrates: Concomitant use with nitrates, which are used to treat chest pain, carries a heightened risk of hypotension. In patients with pre-existing coronary heart disease, an increase or worsening of angina pectoris may occur, potentially requiring discontinuation of Dalfaz.
• Phosphodiesterase-5 (PDE5) Inhibitors: These agents (e.g., sildenafil, tadalafil) are vasodilators, and their co-administration with Dalfaz may also lead to symptomatic hypotension.

The action of Alfuzosin (Dalfaz) is purely mechanistic, focusing on altering the muscle tension within the lower urinary tract by interfering with specific signaling pathways of the autonomic nervous system.

Molecular Mechanism: Blocking Alpha-1 Adrenergic Receptors

The drug's action is peripheral and selectively focused: it functions as a competitive antagonist, binding to and blocking the alpha1-adrenergic receptors (alpha1-AR), particularly the alpha1A subtype, which are prevalent in the smooth muscle of the prostate and bladder neck. This molecular interference prevents the neurotransmitter norepinephrine from binding, thus inhibiting the signaling required for muscle contraction.

Physiological Cascade: Reducing Dynamic Muscular Tension

By blocking the receptor signal, Alfuzosin suppresses the intracellular cascade that regulates smooth muscle tone, specifically by inhibiting the release of intracellular calcium ions ( Ca^2+) necessary for contraction. This functional interruption leads to smooth muscle relaxation within the prostatic urethra. This physiological change functionally produces a reduction in the dynamic resistance within the urethral pathway.

How Dalfaz is Used

Dalfaz (Alfuzosin hydrochloride) is an oral medication, supplied as a 10 mg prolonged-release tablet. The design of this specific tablet formulation is central to its usage, as it ensures a slow and continuous release of the active ingredient over time.

---

Administration and Timing

For the long-term management of symptoms associated with BPH, the standard adult regimen is one 10 mg tablet taken once daily. Due to the medication's absorption characteristics, the tablet must be taken with food and is generally instructed to be taken immediately after the same meal each day to maintain consistent exposure.

---

Handling and Procedural Rules

The prolonged-release integrity must be maintained for proper function. Therefore, the tablet must be swallowed whole with an adequate amount of liquid, such as water. It is an explicit procedural requirement that the tablet must not be chewed, crushed, split, or divided under any circumstances, as this action would compromise the controlled-release mechanism and alter the expected absorption profile.

---

Contextual Usage and Population Rules

While typically used as a long-term regimen for BPH symptom relief, Alfuzosin 10 mg is also used on a short-term basis for approximately three to four days as adjunctive therapy in the management of acute urinary retention (AUR).

In terms of population-specific administration, a dose reduction for older adults (over 65 years) is generally not required. However, this 10 mg extended-release formulation is not indicated for use in the pediatric population (under 18 years).

Research evidence / Overview of studies for Dalfaz

This overview focuses on the official research evidence for Dalfaz (Alfuzosin), detailing the structure of its clinical evaluation, the outcomes that were measured, and what remains uncertain, based on authoritative governmental and peer-reviewed sources.

---

Evidence for Symptom Management of BPH

The research evidence base detailing Dalfaz's clinical evaluation involves multiple, short- and intermediate-term randomized controlled trials (RCTs). These trials were typically double-blind and placebo-controlled and were applied in studies examining patient-reported experiences of men with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).

The main focus of these trials was studied for outcomes related to physical discomfort and functional imbalance. Researchers used standardized tools like the International Prostate Symptom Score (IPSS) and monitored objective changes, such as the Peak Urinary Flow Rate (Q max). Studies monitored over short periods (typically 3 to 6 months) reported findings that describe patterns observed regarding measurements of changes in the average IPSS and shifts in the objective Q max compared to the initial baseline measurements. Research highlights changes measured during the study period concerning patients' Quality of Life (QoL) scores.

Long-Term Studies and Monitoring for BPH Progression

Research studies explored the long-term aspects of Dalfaz in conditions marked by functional limitations and the potential for symptom progression.

One major 2-year, placebo-controlled study was specifically designed to monitor men who were considered at risk for the worsening of their condition. The 2-year progression trial reported no discernible difference between the medicine and control regarding the primary endpoint, which was the first occurrence of Acute Urinary Retention (AUR). However, the study reported patterns related to changes in the rate of the overall clinical progression endpoint, a composite measure that included AUR, BPH-related surgery, and symptom deterioration. Long-term effects are not fully established beyond the two-year mark.

Evidence in Special Populations

The initial clinical evaluation of Dalfaz was evaluated in a wide range of adults, including the older adult population typically affected by BPH.

Studies included a wide range of adults, encompassing the older adult population typically affected by BPH. Regulatory reviews described that in this population, there was no notable relationship observed between the peak plasma concentrations of the medicine and a patient's age. Evidence for Dalfaz is limited regarding its use in patients outside of the adult male population. Specifically, data for certain groups remain insufficient, as there are few data available for children or adolescents. Initial trials often imposed inclusion criteria that limited the enrollment of patients with certain high-risk features, meaning that results apply only to the populations studied.

What is Still Uncertain About the Research for Dalfaz

Official scientific literature highlights several areas where certainty remains low or where the evidence is not yet complete.

The most notable research limitation is the mixed findings reported in the large 2-year progression study. The distinction between no observed impact on the primary event of Acute Urinary Retention and the observed patterns in the secondary, composite outcome of overall clinical progression evidence highlights what is known — and what is still uncertain in this long-term context.

Furthermore, follow-up durations were limited in controlled settings, meaning there is limited information for long-term outcomes beyond the initial two-year period, which may not fully characterize the behavior of the condition over many years. Finally, the evidence quality varies across studies when research has explored non-approved uses, which fall outside the regulatory basis for the medicine.

Common questions about Dalfaz (FAQ)

Q: How long does it typically take for Dalfaz to start working?

A: Official clinical studies indicate that some improvements in urinary flow rate may be observed as early as 24 hours after the first dose. Symptom improvement is commonly noted within one week, and clinical studies report that more pronounced improvements are typically observed around four weeks of continuous use.

Q: Does Dalfaz interact with common over-the-counter pain relievers?

A: Official drug labels primarily list known interactions with specific classes of prescription medicines. The label does not explicitly name or rule out all over-the-counter (OTC) pain relievers as a general category. Regulatory documents note the importance of informing a healthcare provider about all concurrent medications and supplements.

Q: Why is Dalfaz sometimes prescribed with other medications?

A: Regulatory documents specify that Dalfaz is indicated for use as an adjunctive treatment in the management of acute urinary retention (AUR). This means it is used alongside other established treatments, such as a catheter, during the short-term acute phase to help manage the condition.

Q: Does Dalfaz affect sleep patterns?

A: While specific sleep disorders are not typically listed as common side effects, the official safety profile does report side effects related to the central nervous system. These commonly reported effects include fatigue and dizziness, which could potentially influence rest or activity levels.

Q: Are there warnings about driving or operating machinery while using Dalfaz?

A: Official labeling recommends exercising caution and avoiding activities like driving or operating machinery until the effects of the medication are known. This warning is due to the potential risk of dizziness, fainting (syncope), or light-headedness associated with Dalfaz.

Q: How do regulatory bodies classify the safety profile of Dalfaz?

A: The safety profile is structured by official regulatory bodies based on the incidence (frequency) of adverse reactions, categorizing them as Common, Uncommon, or Rare. The profile also identifies conditions and co-administered drugs that are contraindicated (strictly prohibited), such as severe liver impairment or use with strong CYP3A4 inhibitors.

Q: What common foods or drinks are known to interact with Dalfaz?

A: Official regulatory information notes that caution is warranted regarding grapefruit or grapefruit juice. Consumption of grapefruit products may increase the amount of medicine in the bloodstream, which could elevate the risk of experiencing adverse side effects.

Q: What happens if a dose of Dalfaz is missed?

A: Official guidance for a missed dose describes that if a dose is missed, it may be taken when remembered, provided it is not close to the next scheduled dose time. If it is close to the next dose, the official instruction is to let the missed dose go. Regulatory patient information stresses that compensating by taking extra medicine is not advised.

Q: Does Dalfaz have any reported interactions with herbal teas?

A: Specific herbal teas are generally not named in the official drug labels, which focus on chemical interactions with prescription drugs. However, regulatory documents recommend that patients inform their healthcare provider about all non-prescription items they use, including herbal teas and dietary supplements, as some may carry an interaction risk.

Q: Are there reports of Dalfaz causing issues with vision?

A: Official safety documents confirm an association between Dalfaz and a condition called Intraoperative Floppy Iris Syndrome (IFIS). This effect is relevant primarily during cataract or glaucoma surgery. The official labeling states that patients must inform their eye surgeon of current or previous use of this medicine prior to any such procedure.

Q: Are there warnings about combining Dalfaz with alcohol?

A: Yes, regulatory patient information carries warnings about combining Dalfaz with alcohol. Drinking alcohol while using this medicine can potentially increase the risk of side effects such as dizziness, and may further increase the risk of low blood pressure (hypotension).

Q: How quickly is Dalfaz eliminated from the body?

A: Official pharmacokinetic data indicate that the elimination half-life of the extended-release tablet is approximately 9 to 10 hours. The half-life is a measure of the time it takes for the amount of medicine in the body to decrease by half.

How to Store Dalfaz

Dalfaz (alfuzosin hydrochloride extended-release tablets) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product requires strict protection from moisture and must be kept in its original, tightly closed container.

To ensure child safety, the medication must be stored out of the sight and reach of children at all times.

Disposal Requirements

Unused or expired Dalfaz should not be discarded into household waste or flushed down the toilet, as this may impact the environment. Disposal of the medicine or any associated waste material must be carried out in accordance with local pharmaceutical waste requirements.